Forma Therapeutics, whose investors include Eli Lilly and Novartis, has closed its IPO after seeing its shares double in price.

The home care provider has closed a round led by Optum Ventures and backed by Humana and Echo Health Ventures at approximately $136m.

Celgene Switzerland and BMS-backed precision cancer drug developer Repare Therapeutics added $33m to its IPO after its shares rose 65% post-offering.

MemorialCare Innovation Fund contributed to a series D round that brought the heart valve technology developer's overall funding to more than $36m.

MemorialCare Innovation Fund contributed to a series D round that brought the Caltech spinout's overall funding to more than $36m.

Hartford Healthcare returned for a $50m series C round that will support the Stanford spinout in advancing potential treatments for severe liver and inflammatory bowel diseases.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Qiagen-founded precision cancer technology provider agreed to an acquisition by Invitae sized at at least $325m in cash and shares currently valued at about $820m.

Vcanbio scored an exit as the precision cancer treatment and diagnostics developer went public in an upsized offering priced well above its range.

Ona Therapeutics is working on treatments for metastatic cancer and has collected series A funding from investors including Bpifrance.